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An immunogenomic stratiﬁcation of colorectal
cancer: Implications for development of targeted
immunotherapy
Neeraj Lal, Andrew D Beggs, Benjamin E Willcox, and Gary W Middleton*
Cancer Immunology and Immunotherapy Centre; School of Cancer Sciences; University of Birmingham; Birmingham, UK
Keywords: colorectal cancer, immune signature, microsatellite instability, RAS, stratification
Abbreviations: CIRC, Co-ordinate Immune Response Cluster; CMS, consensus molecular subtypes; CRC, colorectal cancer;
CRCSC, colorectal cancer subtyping consortium; MSI-H, microsatellite unstable (high); MSI-L, microsatellite unstable (low);
MSS, microsatellite stable; TCGA, The Cancer Genome Atlas; TILs, tumor-infiltrating lymphocytes
Although tumor inﬁltrating lymphocyte (TIL) density is prognostic and predictive in colorectal cancer (CRC), the
impact of tumor genetics upon colorectal immunobiology is unclear. Identiﬁcation of genetic factors that inﬂuence the
tumor immunophenotype is essential to improve the effectiveness of stratiﬁed immunotherapy approaches. We carried
out a bioinformatics analysis of CRC data in The Cancer Genome Atlas (TCGA) involving two-dimensional hierarchical
clustering to deﬁne an immune signature that we used to characterize the immune response across key patient groups.
An immune signature termed The Co-ordinate Immune Response Cluster (CIRC) comprising 28 genes was coordinately
regulated across the patient population. Four patient groups were delineated on the basis of cluster expression. Group
A, which was heavily enriched for patients with microsatellite instability (MSI-H) and POL mutations, exhibited high CIRC
expression, including the presence of several inhibitory molecules: CTLA4, PDL1, PDL2, LAG3, and TIM3. In contrast, RAS
mutation was enriched in patient groups with lower CIRC expression. This work links the genetics and immunobiology
of colorectal tumorigenesis, with implications for the development of stratiﬁed immunotherapeutic approaches.
Microsatellite instability and POL mutations are linked with high mutational burden and high immune inﬁltration, but
the coordinate expression of inhibitory pathways observed suggests combination checkpoint blockade therapy may be
required to improve efﬁcacy. In contrast, RAS mutant tumors predict for a relatively poor immune inﬁltration and low
inhibitory molecule expression. In this setting, checkpoint blockade may be less efﬁcacious, highlighting a requirement
for novel strategies in this patient group.
Introduction
The density of TILs and the expression of certain immune-
related genes are of prognostic and predictive value in CRC.1–5
However, the factors that determine a patient’s immune pheno-
type are unclear, and few systematic analyses have investigated
the somatic and germline molecular drivers of immune infiltra-
tion. Although, microsatellite unstable (MSI-H) cancers are
known to be associated with increased TIL density,6-12 the nature
of the immune infiltration and the molecular drivers of the
immune phenotype in microsatellite stable (MSS) CRC are
poorly understood. In particular, it is unclear whether defined
molecular subsets (RAS mutant, BRAF mutant, PIK3CA mutant,
quadruple wildtype (BRAF, PIK3CA, NRAS, KRAS all wildtype))
are associated with high or low immune infiltration. In addition,
in both MSI-H and MSS cancers, the extent to which therapeuti-
cally tractable inhibitory immune checkpoint receptors are repre-
sented is unclear and is of substantial interest, particularly
considering recent checkpoint blockade failures in CRC.13,14
Given the prognostic and predictive relevance of CRC immuno-
phenotype, a clearer understanding of the link between immuno-
phenotype with tumor genotype is crucial.
In this study, we carried out a bioinformatics analysis of
CRC data in The Cancer Genome Project (TCGA). Our
analyses defined a co-regulated cluster of immune related
genes with a distinct Th1 bias, expression of which defines
four patient subgroups. The findings have implications for
our understanding of the immunobiology of colorectal carci-
nogenesis, and for development of stratified immunotherapy
approaches for CRC.
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Results
Coordinate expression of immune response-related genes
in colorectal cancer
We interrogated expression of immune response-related genes
in the CRC dataset in the TCGA (nD 195). Preliminary analyses
focused on an initial gene list (Table S1) based partly on previous
studies on bio-molecular networks incorporating immune genes
linked with disease-free survival in CRC.1,4,5 These included
those associated with Th1 subset function (STAT1, IRF1, IFNG,
TBX21, IL18RAP, ICOS, GNLY), certain chemokines
(CX3CL1, CXCL9, CXCL10), adhesion molecules (ICAM and
MADCAM), and an array of class II genes. Also, we included a
number of immune checkpoint genes (PD-1, PD-L1, PD-L2,
LAG3, TIM3, CTLA-4), two of which (PD-L1 and PD-L2)
were previously associated with outcome.4 Finally, our initial
gene list was supplemented with class I genes and additional class
II genes and genes involved in T cell activation, together with
NKG2D ligands and related genes relevant to innate immune
activation (e.g. ULBPs, PROCR15).
We performed unsupervised two-dimensional hierarchical
clustering to assess the extent to which gene expression was co-
ordinate or independent across the patient cohort. Visual analysis
of the clustering highlighted a 28-gene subset (Table 1) which
formed a clear gene grouping, expression of which was coordi-
nately regulated (Fig. S1). Gene-tree analysis of the dendrogram
confirmed the validity of this grouping, identifying a subset of 24
highly coordinated genes (distance threshold 0.46)
predominantly associated with Th1 immunity, including numer-
ous class II MHC loci, and inhibitory molecules targeted in
checkpoint blockade strategies. This 24-gene block was identical
to our 28-gene cluster other than the absence of three additional
class II MHC loci (HLA-DRB5, HLA-DQA2, and HLA-DQA1)
and one additional inhibitory molecule (HAVCR2 (TIM3)), all
of which correlated closely with the 24-gene block and were posi-
tioned directly adjacent on the gene cluster dendrogram. We
therefore, proceeded with the 28-gene cluster as it formed a
clearly coordinated block on visual and correlation analysis. We
termed this grouping the CIRC.
Of the 28 genes in the CIRC, 20 have previously been associ-
ated with outcome based on experimental data.1,4,5 We show
here that these prognostic immune response genes are highly
coordinately expressed in CRC and correlate with other biologi-
cally associated genes including HLA-DQA1, HLA-DRB5, HLA-
DPB1, LAG3, TIM3, CTLA4, and CCL5. The degree of correla-
tion between immune checkpoint receptor/ligand gene expres-
sion was notable (Table S2). Particularly striking was the
correlation between PD1 and LAG3 (r2 D 0.62, Fig. 1). Given
the Th1 bias of the cluster we performed separate unsupervised
hierarchical clustering analysis of Th2 cytokines IL2, IL3, IL4,
IL5, and IL6 and transcription factor GATA3 (data not shown),
revealing that these genes were excluded from the CIRC. We also
note that the Th17 cytokine IL17A was also excluded from the
cluster (Fig. S1).
Molecular determinants of the co-ordinate immune response
cluster
Two-dimensional hierarchical clustering was performed for
the entire gene list (Table S1) incorporating expression data
together with molecular and clinical characteristics (KRAS,
BRAF, NRAS, TP53, PIK3CA, and PTEN mutations; microsatel-
lite status, methylation subtype, tumor stage, tumor site, and
recurrence data). The microsatellite status of the total patient
population was as follows: 11.8% were MSI-H, 15.9% were
MSI-L (microsatellite-low), and 71.8% were MSS. 6.7% of
patients were BRAF mutant (MT)/MSI-H, and 3.1% were BRAF
MT/MSS. The mutational status of the cohort was as follows –
KRAS MT (39.5%), NRAS MT (8.2%), BRAF MT (9.7%),
PIK3CA MT (18.4%), and TP53 MT (51.8%). 38.5% of
patients were quadruple wild type (BRAF WT, KRAS WT, NRAS
WT and PIK3CA WT). We also investigated mutations in the
novel genes POLE (7.2% of patients) and POLD1 (2.6% of
patients), which have recently been highlighted as key drivers of
colorectal carcinogenesis for a minority of CRC patients.16
Hierarchical clustering delineated four distinct patient groups
(Fig. 2, Table 2). Group A patients demonstrated strong CIRC
expression (mean expression 0.98). Notably, all of the MSI-H
patients were included in this group, who constituted 82.1% of
all group A patients, whereas only 10.7% were MSS and 7.1%
were MSI-L. Across the entire cohort, expression of the CIRC
signature was significantly higher in the MSI-H cancers vs. MSS
(p < 0.001) and MSI-L cancers (p < 0.001). Multivariate analy-
sis revealed that expression of HLAA, HLAB, and HLAC were all
significantly less in MSI-H than MSS cancers (p D 0.027, p D
Table 1. Genes within the coordinate immune response cluster (CIRC).
These genes are presented in the order of the CIRC signature
Gene ID
HLA-DQA1
HLA-DQA2
HLA-DRB5
CTLA4
PDCD1LG2
ICAM1
CD274
STAT1
IRF1
IFNG
GNLY
TBX21
CCL5
LAG3
CD247
ICOS
IL18RAP
CXCL9
CXCL10
HLA-DPB1
HLA-DPA1
HLA-DMB
HLA-DRA
HLA-DMA
CD80
HLA-DOA
CD4
HAVCR2
e976052-2 Volume 4 Issue 3OncoImmunology
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0.017, and p D 0.018, respectively for HLA-A, B and C), consis-
tent with previous observations.17 Group A was characterized by
the CpG island methylator phenotype (CIMP-H) (67.9%),
right-sided tumor site (82.1%), TP53 wild type (65%) and
KRAS wild type (82.1%). 50% of patients in this group were
BRAF mutant and of these BRAF mutants, 92.9% were MSI-H.
Notably, POLE and POLD1 mutant tumors were associated with
higher expression of the CIRC (p < 0.05). 42.9% of patients in
group A were either POLE or POLD1 MT, and 70.6% of all
patients with POLE or POLD1 mutations were found in group
A; 100% of POLD1 mutants were assigned to group A. Of the
non-MSI-H patients in group A, 3/5 were POLE mutant, two of
which were MSS and one MSI-L.
We then analyzed patient groups B, C, and D (Fig. 2), which
displayed lower expression of the CIRC signature than group A,
to determine whether any molecular characteristics were associ-
ated with low CIRC expression. Group D comprised cancers
with the lowest expression of the cluster (mean expression –0.62)
and represented 43% of the entire patient population; group B
had a lower mean cluster expression (0.13) than group C (0.50).
Significantly, RAS mutation (KRAS/NRAS), occurring in 47.7%
of patients, was associated with lower CIRC expression
(p < 0.001). This was confirmed in the provisional TCGA data
set, in which mutation and expression data for a further 30
patients (225 total) is available (p < 0.001). The frequency of
RAS mutation was significantly higher in group B and D than
other patient groups (p D 0.01), with group D having the highest
frequency (D (61.9%)>B (51.0%)>C (28.1%)>A (21.4%)), (p
D 0.01). Consistent with these observations, within MSS cancers
(enriched in groups B–D), there was a strong trend for RAS
mutation to be associated with low CIRC expression (p D
0.076). In group A, 83.3% of RAS mutations were MSI-H and
16.7% were MSS (Table 2). In RAS mutant MSI-H patients, the
expression of HLA-DRA was lower (0.518) than in RAS wild
types (1.027) but this difference did not reach significance (p D
0.209). Finally, multivariate analysis indicated that KRAS and
NRAS mutation was associated with decreased CD4 expression
(p < 0.001) (Table S3). The association of low expression of the
cluster and RAS mutation was particularly strong in the case of
NRAS mutation where 76.9% of these cancers were in group D
and over 90% of these tumors clustered in the two lowest expres-
sion groups (B and D). Thus RAS mutation, unless linked with
microsatellite instability, is commonly associated with low levels
of Th1 infiltration and activation, class II expression and inhibi-
tory checkpoint expression. Table 3 shows the distribution of
key mutations.
Several groups have identified molecular subtypes of CRC
based on expression data. In an effort to create consensus, The
Figure 1. Signiﬁcant correlation between LAG3 and PDCD1 (PD1) expression. Pearson correlation analysis indicates the inhibitory molecules LAG3 and
PDCD1 (PD1) are highly coordinated in mRNA expression (R2 D 0.623).
www.tandfonline.com e976052-3OncoImmunology
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colorectal cancer subtyping consortium (CRCSC) have
defined an integrated classification – consensus molecular
subtypes (CMS).18 To investigate how closely our CIRC
patient groupings (based predominantly on immunological
gene expression) correlate with the recently announced CMS
classifications, we retrieved CMS data for the TCGA dataset.
Table 4 shows the distribution of CMS classifications across
our four patient groups. As expected, CMS1, which is a
group comprised of mostly MSI-H and BRAF MT tumors
with strong immunity, falls predominantly within Group A.
Interestingly, 80% of CMS3 tumors, which are epithelial
with KRAS mutations, fall within patient groups B and D,
similar to our KRAS distribution data (Table 3). This reinfor-
ces the hypothesis that KRAS mutant tumors are immunolog-
ically bland. A large proportion of CMS4 tumors, which are
predominantly mesenchymal with a poor prognosis, were
found in patient group B (63.9%), and a large proportion of
CMS2 tumors, which are epithelial with high CIN and
WNT/MYC pathway activation, fall within patient group D
(61.5%). This demonstrates that patient groups B and D are
distinct despite both groups having low CIRC expression
levels.
Discussion
In this study, we identified a group of tightly co-regulated
immune-related genes that we termed the CIRC, and used this
to assess differences in the intra-tumoral immune response in a
molecularly characterized cohort of CRC patients. The CIRC
Table 2. Characteristics of patient groups. For microsatellite status, methylation and tumor side, the most frequent result is stated. Tumor side refers to the
right or left side of the colon. The cluster expression pattern displays the expression pattern of the CIRC cluster in each patient group
Group A Group B Group C Group D
Microsatellite status MSI-H (82%) MSS (86%) MSS (94%) MSS (75%)
MSI-L (25%)
Methylation CIMP-High (68%) CIMP-Neg (77%) CIMP-Neg (66%) CIMP-Neg (69%)
Side of tumour Right (82%) Left (63%) Left (94%) Left (82%)
Stage ICII 73% 55% 72% 49%
TP53 MT 35% 65% 62% 48%
BRAF MT 50% 4% 3% 1%
KRAS MT 18% 47% 22% 49%
NRAS MT 0% 4% 9% 13%
PIK3CA MT 39% 14% 9% 18%
Quadruple WT 18% 39% 69% 33%
Percentage of patients 14% 26% 16% 43%
Mean cluster expression z-score C0.98 C0.13 C0.50 ¡0.62
Cluster expression pattern
Table 3. Frequencies of mutations in total patient population and distribution of mutations across patient groups A–D. We classiﬁed patients initially on the
basis of KRAS status, followed by NRAS, BRAF, and ﬁnally PIK3CA. According to these criteria, KRAS mutations may also have NRAS, BRAF, and PIK3CA muta-
tions (KRASMT C/–NRASMT C/–BRAFMT C/–PIK3CAMT). NRASmutations are KRAS wildtype but may have mutations in BRAF and PIK3CA (KRASWT C NRAS
MT C/–BRAFMT C/–PIK3CAMT). BRAFmutants are KRAS and NRAS wildtype but may have mutations in PIK3CA (KRASWT C NRASWT C BRAFMT C/–PIK3CA
MT). PIK3CA mutants are wildtype for KRAS, NRAS, and BRAF. Quadruple wildtype patients are KRAS, NRAS, BRAF, and PIK3CA wildtype. TP53 mutation status
is independent of other mutations
% of total patient
population
% of total in
patient group A
% of total in
patient group B
% of total in
patient group C
% of total in
patient group D
TP53MT 51.8% 6.9% 32.7% 19.8% 40.6%
BRAFMT 9.2% 72.2% 11.1% 5.5% 11.1%
KRASMT 41.0% 7.5% 30% 10% 52.5%
NRASMT 6.7% 0% 15.4% 7.7% 76.9%
KRAS/NRASMT 47.7% 6.5% 28.0% 9.7% 55.9%
PIK3CAMT 4.1% 50% 37.5% 0% 12.5%
Quadruple wildtype 39.0% 6.6% 26.3% 28.9% 38.2%
www.tandfonline.com e976052-5OncoImmunology
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signature we defined stems from the work of Galon and col-
leagues, who first established the prognostic impact of T cell infil-
tration in CRC, initially highlighting seven co-modulated genes
principally associated with Th1-associated immunity that corre-
lated with outcome.1 Subsequently, they demonstrated that the
Th1 genes, TBX21, IFNG, IRF1 and STAT1 were all individually
associated with outcome.4 Other independent immune gene pre-
dictors in that analysis were IL18RAP, ICOS, PD-L1, PD-L2
and PD-1. We extended this gene list by adding the class I and
class II genes, further immune checkpoint genes and a number of
other genes related to innate immune recognition and T cell acti-
vation, generating an initial gene list of > 50 genes. Unsuper-
vised hierarchical clustering then highlighted a core cluster of 28
tightly co-regulated genes comprising the CIRC signature.
Importantly, 20 of the 28 genes had previously been highlighted
by Galon and colleagues1,4,5 as either prognostically or predic-
tively relevant, including five of the original prognostic seven
gene cluster (with only CD8A (for which microarray data was
unavailable) and GZMB not represented). In contrast, genes
associated with Th2 and Th17 profiles were excluded from the
cluster. Thus, applying a different approach to an independent
data-set our analysis verified the high level of correlation of a
number of genes based on Th1-associated immunity, and also
highlighted involvement of additional immune genes.
An important feature of the CIRC signature is that it includes
essentially all class II MHC loci, as well as CD4, whereas in con-
trast, expression of class I MHC molecules, CD8B and also
GZMB are all excluded from the signature. In addition to the
critical role of T helper cells for CD8C cell priming19,20 and
expansion,21, 22 CD4C cells have also been suggested to be major
mediators of immunological tumor cell death.23-25 Adoptive
CD4C T cell transfer has been found to upregulate class II
expression on tumor cells mediating protection from tumor pro-
gression.24 Class II upregulation was mediated via IFNg and pro-
tection was attenuated using anti-IFNg antibodies. Recent
adoptive transfer approaches involving autologous CD4C T cells
have met with clinical success. A durable complete response was
obtained in a patient with melanoma after infusion of NY-ESO-
1 specific CD4C cells recognizing an HLA-DP4 restricted epi-
tope.26 Additionally, a durable response was obtained in a patient
with cholangiocarcinoma on infusion of autologous mutation-
specific CD4C cells which adopted a poly-functional Th1 pheno-
type.27 These studies highlight the potential for CD4C cells to
mediate clinically potent anti-tumor responses via Th1 mecha-
nisms. The CD4-centric nature of our CIRC highlights that
CD4C T cells may be important in CRC anti-tumor immunity.
The CIRC included the major immune checkpoint molecules.
Not only PD-L1, PD-L2 but also LAG3, TIM3 and CTLA4
were all represented in the CIRC and there was a high degree of
correlation between inhibitory checkpoint gene expression. This
is consistent with the expected feedback sequelae of a pronounced
Th1 infiltrate. IFNg is the canonical cytokine associated with
Th1 T helper cells and expression of PD-L1 is significantly aug-
mented by IFNg.28 IRF1 is of primary importance in the consti-
tutive expression of PD-L1 and in IFNg-driven upregulation.29
In animal models, significant percentages of infiltrating CD4C
and CD8C cells co-express high levels of both PD-1 and LAG-
3.30 Dual anti-LAG3/anti-PD-1 immunotherapy strikingly
enhanced survival in the MC38 colon cancer model compared
with animals treated with single antibodies alone.30 Our data
provide justification for trialing combinations of checkpoint
blockade agents in CRC.
One of the key aims of this study was to investigate the
somatic factors associated with the immune response in CRC.
Group A, which exhibited strong expression of the CIRC signa-
ture, was dominated by MSI-H tumors, all of which fell in this
grouping. This complements very well the work of Biossiere-
Michot and colleagues, who revealed that MSI-H tumors have a
high density of Tbet-positive Th1 T cells relative to MSS
tumors, and higher expression of the chemokines CCL5,
CXCL9, and CXCL10, all of which are found in the CIRC.12
The Th1 response may be driven through activation of the
CXCL9/CXCL10 signaling axis.12 Previous studies have also
shown that MSI-H phenotype is highly associated with class II
expression.31 Strongly DR positive tumors had a significantly
higher TIL density than those with absent or weak staining and
survival was significantly better in patients with high DR expres-
sion. Consistent with this, Bindea and colleagues demonstrated
that the expression of several class II genes, including HLA-
DRA, are individually associated with improved disease-free sur-
vival.5 High DR expression in MSI-H CRC contrasts with that
of class I molecules, which are completely lost in 60% of spo-
radic MSI-H cases and only 16.7% of right sided MSS can-
cers.17 Thus, the immune landscape of MSI-H CRC, which is
characterized by a high mutational burden including frameshift
mutations,10 is dominated by T helper cell infiltration and acti-
vation, class II expression and coordinated upregulation of a
range of immune checkpoint genes. These patients may there-
fore have greater responses to checkpoint blockade therapies.
Similarly, POLE/POLD1 mutant tumors, which also have a
high mutational burden,16 were also associated with high CIRC
expression. These data support the hypothesis that high
Table 4. Distribution of Consensus Molecular Subtype (CMS) groups across CIRC patient groups. The percentage of each CMS group that fall within each
CIRC patient group. 5.1% of TCGA patients did not have CMS classiﬁcation data available
Percentage of total patient population CIRC Group A CIRC Group B CIRC Group C CIRC Group D
CMS1 13.8% 81.5% 7.4% 3.7% 7.4%
CMS2 40.0% 0.0% 15.4% 23.1% 61.5%
CMS3 10.3% 0.0% 30.0% 20.0% 50.0%
CMS4 18.5% 5.6% 63.9% 13.9% 16.7%
Unclassiﬁed 12.3% 12.5% 25.0% 12.5% 50.0%
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mutational burden may translate into a strong immune
response, possibly due to neoantigen presentation, leading to
better outcomes. The finding that the gene encoding TGFbR
undergoes frameshift mutation in 90% of MSI-H CRC, giving
rise to a highly immunogenic promiscuous class II peptide, is
entirely in keeping with this hypothesis.32
RAS mutation was significantly associated with lower CIRC
expression, with over 60% of cancers in the group exhibiting
very low expression (group D) being RAS mutant. KRAS and
NRAS mutant CRC had significantly lower levels of CD4C T
cells on multivariate analysis. Although 21.4% of cancers in
group A were RAS mutant, over 80% of these were MSI-H. This
is the first analysis to our knowledge to clearly define the immu-
nological landscape of RAS mutant CRC. Ogino and colleagues
examined the interaction between T cell infiltration and KRAS,
BRAF, and PIK3CA mutation status and found no significant
associations with KRAS mutation,33 but this study was limited to
the density of CD3C, CD8C, CD45ROC, and FoxP3C cells.
Morris and colleagues demonstrated that transfection of mutant
KRAS into fibroblasts abrogated the IFNg -mediated upregula-
tion of class II expression: effects on class I expression were mini-
mal.34 RAS transfection inhibited proliferation and IFNg
production of alloreactive T cells, an effect mediated by loss of
class II expression on target cells.35 These data suggest a possible
mechanism for our observed paucity of class II expression and
hence Th1-related gene expression in RAS mutant CRC. Our
data complement previous studies demonstrating widespread
abnormalities of class I presentation in RAS mutant CRC.36 In
MSI-H tumors, it is likely that any inhibitory effect of RASmuta-
tion is overcome by the strong immunity resulting from neoanti-
gens linked to mutations induced by microsatellite instability.
Thus MSI-H RAS mutant tumors retain strong Th1 immunity,
despite having numerically lower HLA-DRA expression than
MSI-H RAS wildtype tumors. In sum, these data suggest that the
micro-environment of RAS mutant CRC is relatively immuno-
logically unfavorable to conventional ab T cell responses.
An important consideration is how the CIRC signature relates
to immunosuppressive pathways. Though FOXP3 was not in the
hierarchical clustering due to an absence of microarray data, we
analyzed RNA sequencing data which showed that FOXP3
expression is highest in patient group A and lowest in group D
(data not shown). Additionally, the highly immunosuppressive
cytokine IL10 also exhibited high expression in this patient group
(data not shown), both consistent with increased inhibitory
immunoregulation following establishment of a Th1-polarized
microenvironment. We also analyzed expression of STAT3,
which has been linked to enhanced levels of tumor-associated
macrophages, myeloid-derived suppressor cells, and poor T cell
responses.37,38 Although not strongly linked to the CIRC, we
found increased STAT3 expression was associated with PIK3CA
mutation (Table S3). Conditioned media from PIK3CA mutant
cells has been found to drive STAT3 activation39; Aspirin
decreases STAT3 activation in murine CRC models and pro-
motes apoptosis. Our findings may therefore partly explain previ-
ous molecular epidemiology studies40-42, which have
demonstrated that aspirin usage reduces the risk of CRC
recurrence following resection in patients with CRC harboring
PIK3CA mutations.
The CIRC molecular associations relate to the CRCSC CMS
and their immune and molecular characteristics.18 The majority
of CMS1 patients (MSI high and immune activated) fall within
CIRC group A. 82.5% 0f KRAS mutated patients were in CIRC
groups D and B (the lowest two CIRC expression groups) and
almost the same percentage of CMS3 patients, characterized by
KRAS mutations and no significant immune infiltration and acti-
vation, were present in CIRC groups D and B.
In conclusion, we have shown that MSI-H and POL mutant
CRC is associated with high-level expression of a coordinated
immune response cluster characterized by T helper cell and class
II related genes together alongside a range of chemokines and
immune inhibitory checkpoint molecules. In contrast, RAS
mutant tumors have significantly lower expression of this cluster.
These findings have potential therapeutic implications. MSI-H
tumors may be particularly amenable to CD4C cell expansion
and adoptive transfer approaches. Second, although there is inter-
est in the use of immune checkpoint inhibitors in CRC, the coor-
dinated upregulation of immune checkpoint genes suggests that a
combinatorial approach is likely to be more successful. Finally,
any immunologically based therapy in MSS CRC aimed at RAS
mutant patients must take into account the relatively immuno-
logically quiescent status of the micro-environment in the major-
ity of RAS mutant CRC.
Methods
Gene identification
Genes associated with innate and adaptive tumor immunity in
cancer1,4 and genes relevant to established colon cancer pathways
were shortlisted as initial genes. This list was expanded using
molecular network pathway analysis.43-45 This revealed further
molecules and genes with known genetic, pathway and functional
associations with our initial genes. Genes revealed through this
approach were screened for inclusion into our final gene list based
on known immunological relevance (Table S1).
Data extraction
Normalized Agilent microarray and RNAseq z-score data for
initial genes and mutation data for TP53, KRAS, BRAF, NRAS,
HRAS, PIK3CA and PTEN were extracted from TCGA colorectal
data set46 using the cBioportal tool.43-45 Where expression data
were unavailable, genes were excluded from the analysis. Clinical
data for these patients were retrieved from the TCGA portal
(https://tcga-data.nci.nih.gov/tcga/) and tabulated with genetic
data. CMS data were obtained from the CRCSC through the
Synapse platform (https://www.synapse.org/, Sage Bionetworks).
Data analysis
Data were tabulated in Excel (Microsoft Corp.) and unsuper-
vised two-dimensional hierarchical clustering was performed
using MeV (Dana-Farber Cancer Institute, Boston, MA, USA)
and the Pearson correlation. Patient and gene clusters were
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identified by varying gene-tree distance-thresholds and visual
analysis. Normality of distributions was confirmed with the
Anderson–Darling test. Pearson Coefficient of determination
(R2) values were calculated in Excel and Minitab (Minitab Inc.)
to investigate correlations in gene expression. Gene expression
was correlated against b actin as a control gene. T tests were per-
formed for univariate analyses of normally distributed data, and
Mann–Whitney U tests for non-normally distributed data. Mul-
tivariate linear regression analyses of gene expression against
mutations in key tumor associated genes (P53, KRAS, BRAF,
NRAS, HRAS, PI3KCA, PTEN) were completed in Stata 12.2
(Statacorp.). For two by two comparisons, a Chi-squared test was
used; if any groups contained less than five values, the Fisher’s
Exact test was used in preference.
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.
Acknowledgments
The authors thank the Colorectal Cancer Subtyping Consor-
tium for kindly providing CMS classifications for the TCGA
dataset.
Funding
NL is supported by a Cancer Research UK clinical PhD stu-
dentship. ADB is supported by a Wellcome Trust Postdoctoral
Training fellowship for Clinician Scientists (ref 102732/Z/13/
Z). BW is supported by a Wellcome Trust New Investigator
Award (099266/Z/12/Z). GM is supported by Cancer Research
UK.
Supplemental Material
Supplemental data for this article can be accessed on the
publisher’s website.
References
1. Galon J. Type, Density, and Location of immune cells
within human colorectal tumors predict clinical out-
come. Science 2006; 313:1960-4; PMID:17008531;
http://dx.doi.org/10.1126/science.1129139
2. Galon J, Pages F, Marincola FM, Angell HK, Thurin
M, Lugli A, Zlobec I, Berger A, Bifulco C, Botti G
et al. Cancer classification using the Immunoscore: a
worldwide task force. J Trans Med 2012; 10:205;
PMID:23034130; http://dx.doi.org/10.1186/1479-
5876-10-205
3. Galon J, Pages F, Marincola FM, Thurin M, Trinchieri
G, Fox BA, Gajewski TF, Ascierto PA. The immune
score as a new possible approach for the classification of
cancer. J Trans Med 2012; 10:1; PMID:22214470;
http://dx.doi.org/10.1186/1479-5876-10-1
4. Mlecnik B, Tosolini M, Charoentong P, Kirilovsky A,
Bindea G, Berger A, Camus M, Gillard M, Bruneval P,
Fridman WH et al. Biomolecular network reconstruc-
tion identifies T-Cell homing factors associated with
survival in colorectal cancer. Gastroenterology 2010;
138:1429-40; PMID:19909745; http://dx.doi.org/
10.1053/j.gastro.2009.10.057
5. Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Wald-
ner M, Obenauf AC, Angell H, Fredriksen T, Lafon-
taine L, Berger A et al. Spatiotemporal dynamics of
intratumoral immune cells reveal the immune land-
scape in human cancer. Immunity 2013; 39:782-95;
PMID:24138885; http://dx.doi.org/10.1016/j.immuni.
2013.10.003
6. Kim H, Nam SW, Rhee H, Shan Li L, Ju Kang H, Hye
KohK, KyuKimN, Song J, Tak-Bun Liu E, KimH.Dif-
ferent gene expression profiles between microsatellite
instability-high and microsatellite stable colorectal carci-
nomas. Oncogene 2004; 23:6218-25; PMID:15208663;
http://dx.doi.org/10.1038/sj.onc.1207853
7. Phillips SM, Banerjea A, Feakins R, Li SR, Bustin SA,
Dorudi S. Tumour-infiltrating lymphocytes in colorec-
tal cancer with microsatellite instability are activated
and cytotoxic. British J Surg 2004; 91:469-75;
PMID:15048750; http://dx.doi.org/10.1002/bjs.4472
8. Buckowitz A, Knaebel HP, Benner A, Bl€aker H, Gebert
J, Kienle P, von Knebel Doeberitz M, Kloor M. Micro-
satellite instability in colorectal cancer is associated
with local lymphocyte infiltration and low frequency of
distant metastases. British J Cancer 2005; 92:1746-53;
PMID:15856045; http://dx.doi.org/10.1038/sj.bjc.
6602534
9. Banerjea A, Bustin SA, Dorudi S. The immunogenicity
of colorectal cancers with high-degree microsatellite
instability. World J Surg Oncol 2005; 3:26;
PMID:15890075; http://dx.doi.org/10.1186/1477-
7819-3-26
10. Jass JR. Classification of colorectal cancer based on corre-
lation of clinical, morphological and molecular features.
Histopathology 2007; 50:113-30; PMID:17204026;
http://dx.doi.org/10.1111/j.1365-2559.2006.02549.x
11. Fehlker M, Huska MR, J€ons T, Andrade-Navarro MA,
Kemmner W. Concerted down-regulation of immune-
system related genes predicts metastasis in colorectal carci-
noma. BMC Cancer 2014; 14:64; PMID:24495478;
http://dx.doi.org/10.1186/1471-2407-14-64
12. Boissiere-Michot F, Lazennec G, Frugier H, Jarlier M,
Roca L, Duffour J, Du Paty E, Laune D, Blanchard F, Le
Pessot F et al. Characterization of an adaptive immune
response in microsatellite-instable colorectal cancer.
OncoImmunology 2014; 3:e29256; PMID:25101223;
http://dx.doi.org/10.4161/onci.29256
13. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN,
Smith DC, McDermott DF, Powderly JD, Carvajal
RD, Sosman JA, Atkins MB et al. Safety, activity, and
immune correlates of anti-PD-1 antibody in cancer. N
Engl J Med 2012; 366:2443-54; PMID:22658127;
http://dx.doi.org/10.1056/NEJMoa1200690
14. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topa-
lian SL, Hwu P, Drake CG, Camacho LH, Kauh J,
Odunsi K et al. Safety and activity of anti-PD-L1 anti-
body in patients with advanced cancer. N Engl J Med
2012; 366:2455-65; PMID:22658128; http://dx.doi.
org/10.1056/NEJMoa1200694
15. Willcox CR, Pitard V, Netzer S, Couzi L, Salim M, Sil-
berzahn T, Moreau J-F, Hayday AC, Willcox BE,
Dechanet-Merville J. Cytomegalovirus and tumor stress
surveillance by binding of a human gd T cell antigen
receptor to endothelial protein C receptor. Nat Immu-
nol 2012; 13:872-9; PMID:22885985; http://dx.doi.
org/10.1038/ni.2394
16. Palles C, Cazier JB, Howarth KM, Domingo E, Jones
AM, Broderick P, Kemp Z, Spain SL, Guarino E, Sal-
guero I et al. Germline mutations affecting the proof-
reading domains of POLE and POLD1 predispose to
colorectal adenomas and carcinomas. Nat Genet 2013;
45:136-44; PMID:23263490; http://dx.doi.org/
10.1038/ng.2503
17. Dierssen JW, de Miranda NF, Ferrone S, van Puijen-
broek M, Cornelisse CJ, Fleuren GJ, van Wezel T,
Morreau H. HNPCC versus sporadic microsatellite-
unstable colon cancers follow different routes toward
loss of HLA class I expression. BMC Cancer 2007;
7:33; PMID:17316446; http://dx.doi.org/10.1186/
1471-2407-7-33
18. Dienstmann R, Guinney J, Delorenzi M, De Reynies
A, Roepman P, Sadanandam A, Vermeulen L, Schlicker
A, Missiaglia E, Soneson C et al. Colorectal Cancer
Subtyping Consortium (CRCSC) identification of a
consensus of molecular subtypes. ASCO Meeting
Abstracts 2014; 32:3511.
19. Bennett SR, Carbone FR, Karamalis F, Miller JF,
Heath WR. Induction of a CD8C cytotoxic T lympho-
cyte response by cross-priming requires cognate CD4C
T cell help. J Exp Med 1997; 186:65-70;
PMID:9206998; http://dx.doi.org/10.1084/jem.186.
1.65
20. Bennett SR, Carbone FR, Karamalis F, Flavell RA,
Miller JF, Heath WR. Help for cytotoxic-T-cell
responses is mediated by CD40 signalling. Nature
1998; 393:478-80; PMID:9624004; http://dx.doi.org/
10.1038/30996
21. Janssen EM, Lemmens EE, Wolfe T, Christen U, von
Herrath MG, Schoenberger SP. CD4C T cells are
required for secondary expansion and memory in
CD8C T lymphocytes. Nature 2003; 421:852-6;
PMID:12594515; http://dx.doi.org/10.1038/nature
01441
22. WilliamsMA, Tyznik AJ, BevanMJ. Interleukin-2 signals
during priming are required for secondary expansion of
CD8C memory T cells. Nature 2006; 441:890-3;
PMID:16778891; http://dx.doi.org/10.1038/nature
04790
23. Xie Y, Akpinarli A, Maris C, Hipkiss EL, Lane M,
Kwon EK, Muranski P, Restifo NP, Antony PA. Naive
tumor-specific CD4(C) T cells differentiated in vivo
eradicate established melanoma. J Exp Med 2010;
207:651-67; PMID:20156973; http://dx.doi.org/
10.1084/jem.20091921
24. Quezada SA, Simpson TR, Peggs KS, Merghoub T,
Vider J, Fan X, Blasberg R, Yagita H, Muranski P, Ant-
ony PA et al. Tumor-reactive CD4(C) T cells develop
cytotoxic activity and eradicate large established mela-
noma after transfer into lymphopenic hosts. J Exp Med
2010; 207:637-50; PMID:20156971; http://dx.doi.
org/10.1084/jem.20091918
25. Haabeth OA, Tveita AA, Fauskanger M, Schjesvold F,
Lorvik KB, Hofgaard PO, Omholt H, Munthe LA,
Dembic Z, Corthay A et al. How Do CD4(C) T Cells
Detect and Eliminate Tumor Cells That Either Lack or
Express MHC Class II Molecules? Front Immunol
2014; 5:174; PMID:24782871; http://dx.doi.org/
10.3389/fimmu.2014.00174
26. Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly
JZ, Rodmyre R, Jungbluth A, Gnjatic S, Thompson
JA, Yee C. Treatment of metastatic melanoma with
autologous CD4C T cells against NY-ESO-1. N Engl J
Med 2008; 358:2698-703; PMID:18565862; http://
dx.doi.org/10.1056/NEJMoa0800251
e976052-8 Volume 4 Issue 3OncoImmunology
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ity
 of
 B
irm
ing
ha
m]
 at
 07
:08
 06
 Ju
ly 
20
15
 
27. Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley
ME, Wunderlich JR, Somerville RP, Hogan K, Hinrichs
CS et al. Cancer immunotherapy based on mutation-spe-
cific CD4C T cells in a patient with epithelial cancer. Sci-
ence 2014; 344:641-5; PMID:24812403; http://dx.doi.
org/10.1126/science.1251102
28. Dong H, Strome SE, Salomao DR, Tamura H, Hirano
F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K et al.
Tumor-associated B7-H1 promotes T-cell apoptosis: a
potential mechanism of immune evasion. Nat Med
2002; 8:793-800; PMID:12091876; http://dx.doi.org/
10.1038/nm0902-1039c
29. Lee SJ, Jang BC, Lee SW, Yang YI, Suh SI, Park YM,
Oh S, Shin JG, Yao S, Chen L et al. Interferon regula-
tory factor-1 is prerequisite to the constitutive expres-
sion and IFN-gamma-induced upregulation of B7-H1
(CD274). FEBS Lett 2006; 580:755-62;
PMID:16413538; http://dx.doi.org/10.1016/j.febslet.
2005.12.093
30. Woo SR, Turnis ME, Goldberg MV, Bankoti J, Selby
M, Nirschl CJ, Bettini ML, Gravano DM, Vogel P,
Liu CL et al. Immune inhibitory molecules LAG-3 and
PD-1 synergistically regulate T-cell function to pro-
mote tumoral immune escape. Cancer Res 2011;
72:917-27; PMID:22186141; http://dx.doi.org/
10.1158/0008-5472.CAN-11-1620
31. Løvig T, Andersen SN, Thorstensen L, Diep CB,
Meling GI, Lothe RA, Rognum TO. Strong HLA-DR
expression in microsatellite stable carcinomas of the
large bowel is associated with good prognosis. British J
Cancer 2002; 87:756-62; PMID:12232760; http://dx.
doi.org/10.1038/sj.bjc.6600507
32. Saeterdal I, Bjorheim J, Lislerud K, Gjertsen MK,
Bukholm IK, Olsen OC, Nesland JM, Eriksen JA,
Moller M, Lindblom A et al. Frameshift-mutation-
derived peptides as tumor-specific antigens in inherited
and spontaneous colorectal cancer. Proc Natl Acad Sci
U S A 2001; 98:13255-60; PMID:11687624; http://
dx.doi.org/10.1073/pnas.231326898
33. Nosho K, Baba Y, Tanaka N, Shima K, Hayashi M,
Meyerhardt JA, Giovannucci E, Dranoff G, Fuchs CS,
Ogino S. Tumour-infiltrating T-cell subsets, molecular
changes in colorectal cancer, and prognosis: cohort
study and literature review. J Pathol 2010; 222:350-66;
PMID:20927778; http://dx.doi.org/10.1002/path.
2774
34. Maudsley DJ, Morris AG. Kirsten murine sarcoma virus
abolishes interferon gamma-induced class II but not class
I major histocompatibility antigen expression in a murine
fibroblast line. J Exp Med 1988; 167:706-11;
PMID:2831293; http://dx.doi.org/10.1084/jem.167.
2.706
35. Maudsley DJ, Bateman WJ, Morris AG. Reduced stim-
ulation of helper T cells by Ki-ras transformed cells.
Immunology 1991; 72:277-81; PMID:1826672
36. Atkins D, Breuckmann A, Schmahl GE, Binner P, Fer-
rone S, Krummenauer F, St€orkel S, Seliger B. MHC
class I antigen processing pathway defects, ras muta-
tions and disease stage in colorectal carcinoma. Int J
Cancer 2004; 109:265-73; http://dx.doi.org/10.1002/
ijc.11681
37. Kortylewski M, Yu H. Role of Stat3 in suppressing
anti-tumor immunity. Curr Opin Immunol 2008;
20:228-33; PMID:18479894; http://dx.doi.org/
10.1016/j.coi.2008.03.010
38. Melief CJ. Cancer immunotherapy by dendritic cells.
Immunity 2008; 29:372-83; PMID:18799145; http://
dx.doi.org/10.1016/j.immuni.2008.08.004
39. Hutti JE, Pfefferle AD, Russell SC, Sircar M, Perou
CM, Baldwin AS. Oncogenic PI3K mutations lead to
NF-kappaB-dependent cytokine expression following
growth factor deprivation. Cancer Res 2012; 72:3260-
9; PMID:22552288; http://dx.doi.org/10.1158/0008-
5472.CAN-11-4141
40. Thun MJ, Namboodiri MM, Heath CW, Jr. Aspirin
use and reduced risk of fatal colon cancer. N Engl J
Med 1991; 325:1593-6; PMID:1669840; http://dx.
doi.org/10.1056/NEJM199112053252301
41. Liao X, Lochhead P, Nishihara R, Morikawa T,
Kuchiba A, Yamauchi M, Imamura Y, Qian ZR, Baba
Y, Shima K et al. Aspirin use, tumor PIK3CA muta-
tion, and colorectal-cancer survival. New Eng J Med
2012; 367:1596-606; PMID:23094721; http://dx.doi.
org/10.1056/NEJMoa1207756
42. Domingo E, Church DN, Sieber O, Ramamoorthy R,
Yanagisawa Y, Johnstone E, Davidson B, Kerr DJ,
Tomlinson IP, Midgley R. Evaluation of PIK3CA
mutation as a predictor of benefit from nonsteroidal
anti-inflammatory drug therapy in colorectal cancer. J
Clin Oncol 2013; 31:4297-305; PMID:24062397;
http://dx.doi.org/10.1200/JCO.2013.50.0322
43. Cbioportal for Cancer Genomics. Memorial Sloan Ket-
tering Cancer Center.
44. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B,
Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E
et al. Integrative analysis of complex cancer genomics
and clinical profiles using the cBioPortal. Sci Signal
2013; 6:pl1.
45. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO,
Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson
E et al. The cBio cancer genomics portal: an open plat-
form for exploring multidimensional cancer genomics
data. Cancer Discov 2012; 2:401-4; PMID:22588877;
http://dx.doi.org/10.1158/2159-8290.CD-12-0095
46. Comprehensive molecular characterization of human
colon and rectal cancer. Nature 2012; 487:330-7;
PMID:22810696; http://dx.doi.org/10.1038/nature
11252
www.tandfonline.com e976052-9OncoImmunology
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ity
 of
 B
irm
ing
ha
m]
 at
 07
:08
 06
 Ju
ly 
20
15
 
